Overview of 3 studies on CLL therapy: data on ibrutinib and a ROR1 inhibitor

Overview of 3 studies on CLL therapy: data on ibrutinib and a ROR1 inhibitor

VJHemOnc

3 years
282 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Anders Österborg, MD, PhD from the Karolinska Hospital & Institute, Stockholm in Sweden gives an overview of the data presented by his group at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
The first real-world data on ibrutinib in 97 patients with relapsed/refractory chronic lymphocytic leukemia (CLL), demonstrated that the overall efficacy of this drug was in line with the results of the clinical trials that preceded this study. The progression-free survival (PFS) data was also in line with the clinical trials results.
An analysis of historical data from the period between 2002-2013 showed that CLL therapy did not improve much during that time, despite the release of new agents.
Another set of data on a ROR1 inhibitor, showed that it was effective in vitro. ROR1 is a receptor tyrosine kinase (RTK) that is expressed by CLL and other tumors. The group hopes that this drug candidate can be taken forward to a Phase I clinical trial.
Up Next Autoplay
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 2 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 2 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 2 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
0 Views
Cancer-News 2 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
0 Views
Cancer-News 2 days
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Category: News
1 Views
ash 2 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 4 days
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Category: Brain Cancer
5 Views
Cancer-News 5 days
Molecular AI Product: What's Next For Research?
Molecular AI Product: What's Next For Research?
Category: News
11 Views
Cancer-News 1 week
Molecular AI Product: Can It Be Used Now or Later?
Molecular AI Product: Can It Be Used Now or Later?
Category: News
9 Views
Cancer-News 1 week